Cell­tri­on teams up with an­oth­er Ko­re­an bio­phar­ma in an­ti­body dis­cov­ery deal

Two Ko­re­an com­pa­nies have signed a joint R&D dis­cov­ery agree­ment, with the po­ten­tial to earn in the nine-fig­ures.

Clin­i­cal-stage bio­phar­ma Genuv has part­nered up with Cell­tri­on to dis­cov­er an­ti­bod­ies us­ing the for­mer’s Shine Mouse plat­form, which they hope could po­ten­tial­ly open up more R&D projects to­geth­er in the fu­ture. There’s no up­front cash, but Genuv will re­ceive mile­stone pay­ments of up to $25 mil­lion if Cell­tri­on de­cides to op­tion a pro­gram in­to the clin­ic, and up to $680 mil­lion in mile­stones per pro­gram if its sales sur­pass $7.5 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.